SMMT's shares plunge 20% as the FDA issues a CRL for ivonescimab, citing insufficient overall survival evidence despite positive progression-free survival results.
SMMT's shares plunge 20% as the FDA issues a CRL for ivonescimab, citing insufficient overall survival evidence despite positive progression-free survival results.
Aura completes phase III enrollment for bel-sar, with pivotal data expected in 2027 and additional ocular cancer programs expanding its growth potential.
Beam Therapeutics reports positive BEACON study results for risto-cel in sickle cell disease, paving the way for a potential FDA filing by year-end 2026.
AC Immune (ACIU) delivered earnings and revenue surprises of +27.27% and +299.42%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?